New Study Shows AI-powered Imaging Software Platform Enables Earlier Detection of Progressive Pulmonary Fibrosis

▤ Summary

Brainomix says new study results show its AI-powered e-Lung imaging platform could help clinicians detect progressive pulmonary fibrosis much earlier. The company reports that the software automatically analyzes CT scans to identify subtle progression over time and support treatment decisions. Research presented at CHEST suggests the platform could have accelerated diagnosis in a majority of patients and identified progression in clinically stable cases. The findings reinforce the value of AI-driven imaging tools in respiratory care and highlight a potential path to broader clinical adoption.

▦ Linked Companies

Brainomix

$1M to $5M